LAB Overview

Standard BioTools Inc. develops, manufactures and sells a diversified range of instrumentation, consumables, and services that help scientists and biomedical researchers. The Company's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The Company works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. It offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.

Wall Street analysts forecast LAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LAB is1.35 USD with a low forecast of 1.35 USD and a high forecast of 1.35 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Standard BioTools Inc revenue for the last quarter amounts to 23.80M USD, decreased -49.07

Standard BioTools Inc. EPS for the last quarter amounts to 0.05 USD, decreased -155.56

Standard BioTools Inc (LAB) has 818 emplpoyees as of March 11 2026.

Today LAB has the market capitalization of 380.68M USD.